January 19, 2007 — The European Commission has approved levetiracetam for the adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older with refractory ...
- Data Published in the British Journal of Cancer Reports ThatNeoRecormon use has no Negative Impact on Overall Survival or TumourProgression These encouraging results reported in the British Journal ...
ZURICH, Jan 10 (Reuters) - Swiss drugmaker Roche said on Wednesday the European Union had approved its NeoRecormon for once-weekly injection to treat cancer patients suffering from anaemia. The ...
-- Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results